← Guides

How do you speed up deviation investigations without weakening them?

By Savi C., Co-Founder · Published Nov 16, 2026

What an investigation has to contain

21 CFR 211.100(b) requires any deviation from written procedures to be recorded and justified. 21 CFR 211.192 requires unexplained discrepancies to be thoroughly investigated whether or not the batch has been distributed, extended to other batches of the same product and other products that may be affected, with a written record of conclusions and follow-up.

EU GMP Chapter 1, paragraph 1.4(xiv), asks for an appropriate level of root cause analysis determined using quality risk management. Where the true root cause cannot be found, the most likely cause should be identified and addressed. Where human error is named as the cause, it should be justified, having made sure process, procedural or system causes were not overlooked. Those are the parts you cannot shorten.

Where time goes, and what to do about it

Where time is lost

Every deviation treated with the same process

What speeds it up

Risk-based classification at intake, with a lighter documented path for minor events

Where time is lost

Searching for the batch record pages, logbooks and results that matter

What speeds it up

Evidence located and linked to its source page before the investigator starts

Where time is lost

Checking whether the same thing happened before

What speeds it up

Searchable history of deviations by product, step, equipment and cause

Where time is lost

Working out which other batches are affected

What speeds it up

A defined impact assessment template and access to the same data across batches

Where time is lost

Waiting for interviews and reviews

What speeds it up

Named owners, due dates per stage and escalation when a stage stalls

Where time is lost

Rewriting the report after QA review

What speeds it up

A standard report structure that QA has agreed in advance

Speed without weakening: a checklist

Keep

  • A clear problem statement: what happened, where, when, which batches
  • Root cause analysis to the depth the risk requires, with the method recorded
  • Impact assessment on the batch, on other batches and on other products
  • Justification whenever human error is named as the cause
  • CAPA tied to the root cause, with an effectiveness check planned

Cut

  • Manual hunting for evidence that already exists in records
  • Full investigation templates for events your procedure classifies as minor
  • Hand-offs with no owner or due date
  • Report rework caused by unclear expectations

Watch for

  • Human error and retraining as the default conclusion
  • Investigations closed on time but reopened by recurrence
  • Impact assessments that only look at the batch in hand

The best investigation is the one that starts early

An investigation is faster when the deviation is found close to when it happened. A discrepancy spotted during batch record review, weeks after the batch was made, means memories have faded and nearby batches may already be affected. Checking records as they are produced, rather than at the end, shortens the investigation before it begins.

For laboratory results, FDA’s guidance on investigating out-of-specification results, revised in May 2022, describes a phased approach that starts with a laboratory investigation before a full-scale investigation. The same principle applies elsewhere: rule out the simple explanations quickly and with evidence, then go deep where it matters.

Measure the process, not only the clock. Track how long each stage takes, how often investigations are extended, and how often a closed investigation is followed by the same deviation. A faster average that comes with more recurrence is not an improvement, and the recurrence figure is the one an inspector is likely to look at.

How Litewave fits

Litewave reads paper or electronic records, checks every entry against your master record and specifications, and shows QA only the exceptions, each linked to the page it came from. For investigations, that means discrepancies surface earlier and the evidence behind them is already linked to its source. Litewave proposes, qualified people approve: the root cause, impact assessment and CAPA remain your investigators’ judgment.

Questions we get asked

Is there a regulatory deadline for closing a deviation?

US and EU GMP regulations do not set a fixed number of days for deviation investigations. Sites set their own targets in procedures, and investigators will expect you to meet them, or to document why an investigation was extended.

Can minor deviations skip root cause analysis?

They can have a lighter one. EU GMP Chapter 1 asks for an appropriate level of root cause analysis determined by quality risk management, and ICH Q10 asks for effort commensurate with risk. The classification and its rationale should be documented.

Can AI write the investigation report?

It can help assemble evidence and draft sections, but the conclusions, root cause and impact assessment need to be made and approved by qualified people, and the report should show the evidence each conclusion rests on.

Sources

  1. 21 CFR 211.100, Written procedures; deviations (eCFR)
  2. 21 CFR 211.192, Production record review (eCFR)
  3. EudraLex Volume 4, Part I, Chapter 1, Pharmaceutical Quality System
  4. ICH Q10, Pharmaceutical Quality System
  5. FDA, Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production, Revision 1 (May 2022)